12:00 AM
 | 
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Jetrea ocriplasmin regulatory update

ThromboGenics said the U.K.'s NICE selected Jetrea ocriplasmin to receive a single technology appraisal to treat symptomatic vitreomacular adhesion (VMA). The product is under review in the EU...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >